Acute pulmonary thromboembolism occurring during treatment with tolvaptan in a patient with autosomal-dominant polycystic kidney disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Acute pulmonary thromboembolism occurring during treatment with tolvaptan in a patient with autosomal-dominant polycystic kidney disease

Published:2017-01-24 Issue:1 Volume:6 Page:61-65
ISSN:2192-4449
Container-title:CEN Case Reports
language:en
Short-container-title:CEN Case Rep

Author:

Morimoto Katsuhiko,Akai Yasuhiro,Matsui Masaru,Yano Hiroki,Tagawa Miho,Samejima Ken-ichi,Saito Yoshihiko

Funder

Merck

Takeda Pharmaceutical Company

Novartis Pharma KK

Daiichi Sankyo Company

Mitsubishi Tanabe Pharma Corp

Pfizer Japan

Otsuka Pharmaceutical

Research funding from Japan Heart Foundation and the Naito Foundation

Dainippon-Sumitomo Pharmaceutical Company

Research funding from Nara Red Cross Blood Distributing Center

Publisher

Springer Science and Business Media LLC

Subject

General Earth and Planetary Sciences,General Environmental Science

Link

http://link.springer.com/article/10.1007/s13730-016-0245-y/fulltext.html

Reference15 articles.

1. Higashihara E, Nutahara K, Kojima M, Tamakoshi A, Yoshiyuki O, Sakai H, et al. Prevalence and renal prognosis of diagnosed autosomal dominant polycystic kidney disease in Japan. Nephron. 1998;80:421–7.

2. Gattone VH 2nd, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003;9:1323–6.

3. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407–18.

4. Yasaka M, Beppu S. Hypercoagulability in the left atrium: Part II: Coagulation factors. J Heart Valve Dis. 1993;2:25–34. discussion 35–6.

5. Kawakami S, Kaibara M, Kawamoto Y, Yamanaka K. Rheological approach to the analysis of blood coagulation in endothelial cell-coated tubes: activation of the intrinsic reaction on the erythrocyte surface. Biorheology. 1995;32:521–36.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High prevalence of thromboembolic events in autosomal dominant polycystic kidney disease: a longitudinal study;Journal of Nephrology;2024-08-05

2. The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: A systematic review and meta-analysis;Nefrología (English Edition);2023-11

3. The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: A systematic review and meta-analysis;Nefrología;2022-10

4. Recurrent thromboses and major vessel compressions in autosomal dominant polycystic kidney disease;Journal of Surgical Case Reports;2022-02-01

5. Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry;Kidney International Reports;2021-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3